
Active Complement Component 8b (C8b)

Catalog#:PEH12642

概述（Summary）

别称（Alternative Names）	Complement component 8 subunit beta
纯度（Purity）	Greater than 90% as determined by reducing SDS-PAGE.
内毒素（Endotoxin level）	Please contact with the lab for this information
蛋白构建（Construction）	【Cys162-His504】
Accession #	P07358
表达宿主（Host）	E.coli
种属（Species）	Homo sapiens (Human)
预测分子量（Predicted MW）	43.2 kDa
制剂（Form）	Lyophilized from a 0.2 μm filtered solution of PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
运输方式（Shipping）	The product is shipped with ice bag. Upon receipt, store it immediately at the temperature listed below.
稳定性&储存（Stability &Storage）	12 months at -20°C to -80°C in lyophilized state.6 months at -20°C to -80°C under sterile conditions after reconstitution.7-10 days at 2°C to 8°C under sterile conditions after reconstitution.Please minimize freeze-thaw cycles.
复溶（Reconstitution）	Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
背景介绍（References）	Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells.

电泳图（SDS-PAGE image）



Greater than 90% as determined by reducing SDS-PAGE.

活性图（Bioactivity image）




Figure 1. The binding activity of recombinant human C8b and recombinant human C9

Complement Component 8b (C8b), one of the three subunits of the complement component 8 (C8) protein, has only been identified in vertebrates. C8 is one of the five components (C5b, C6, C7, C8 and C9) that interact to form the MAC that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. Besides, C9 can interact with C8b, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human C8b and recombinant human C9. Briefly, C8b was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to C9-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-C8b pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human C8b and recombinant human C9 was shown in Figure 1, the EC50 for this effect is 0.59 ug/mL.

注意事项（Note）

For Research Use Only , Not for Diagnostic Use.